Waters Corporation (NYSE: WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE: BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies, and an industry-leading financial outlook. The Company also announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors (the "Waters Board"), increasing the size of the Waters Board to a total of 11 members.

On December 2, 2025, Merck announced that Rogier Janssens will officially assume the role of President of Merck China starting February 1, 2026.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 fourth quarter and full year, which ended September 30, 2025.

Waters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced a definitive agreement to combine BD’s Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook. The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion.

SCIEX, a global leader in life science analytical technologies, announces Chris Hagen as President, effective immediately. Hagen joins SCIEX from Beckman Coulter Diagnostics, a fellow Danaher operating company, where he most recently served as Senior Vice President and General Manager of Core Lab Specialty Solutions. As President of SCIEX, Hagen aims to motivate operational and commercial excellence while pushing the boundaries of innovation in analytical science.

Dotmatics®, a leading provider of scientific software that provides end-to-end solutions to connect science, data, and decision making for life sciences R&D, today announced it has signed a definitive agreement to be acquired by Siemens AG for $5.1 billion.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023.

PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower life science innovations.